Menarini Diagnostics acquires EOS Preanalytics and Point Of Care company assets
Created by on 1/15/2021 6:23:41 PM

FLORENCE, January 15th, 2021



Menarini Diagnostics acquires EOS Preanalytics and Point Of Care company assets

FLORENCE, January 15th, 2021 - Menarini Diagnostics, a company of the Menarini Group, leader in the supply of diagnostic solutions, and EOS, an Italian company focused on the development of innovative new generation diagnostic devices, have announced the transfer of the Point-Of-Care and Preanalitics business from EOS to Menarini.
The EOS Point-Of-Care portfolio represents a complete offer for a decentralized diagnostic response in the field of infectious disease, clinical chemistry, hematology, coagulation and immunoassays allowing Menarini to further expand its role in this strategic segment. Supported and integrated by dedicated IT governance and traceability platforms, the solutions dedicated to Preanalytics represent one of the most extensive and innovative proposals in the field of Laboratory Medicine allowing a complete automation of sampling, integrated logistics, traceability and sample management.

Fabio Sgarabottolo, CEO and President of EOS, commented: "Menarini has a long-standing experience in the laboratory diagnostics sector as a whole, as well as an in-depth knowledge of the Point Of Care and Sample Management. The portfolio of the company, the experience in the introduction of innovative systems and the knowledge of the marketing and sales teams led us to choose Menarini as a partner for speeding up the introduction of these innovative solutions in the domestic and international markets".

Fabio Piazzalunga, General Manager & Global Head of A. Menarini Diagnostics, stated: "Menarini confirms its commitment and willingness to keep on investing in Italy and in particular in the Point-Of-Care and in the critical areas of Preanalytics for the automation of patient samples management. In these years, EOS achieved a leading market position in these sectors and the product portfolio covered by this acquisition is in line with Menarini Diagnostics' strategy aimed at a continuous improvement in the decentralized diagnostic response and safer pre-analytical routines bringing better solutions for patients and healthcare professionals".